



ncbi.nlm.nih.gov/pubmed/18082216.

10. Roehrborn CG, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. *Eur Urol* 2010; 57: 123. <https://www.ncbi.nlm.nih.gov/pubmed/19825505>.

11. Karavitakis M, et al. Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis. *Eur Urol* 2019; 75: 788. <https://www.ncbi.nlm.nih.gov/pubmed/30773327>.

12. Welk B, et al. The risk of fall and fracture with the initiation of a prostate-selective alpha antagonist: a population based cohort study. *BMJ* 2015; 351: h5398. <https://www.ncbi.nlm.nih.gov/pubmed/26502947>.

13. Van Dijk MM, et al. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. *Drugs* 2006; 66: 287. <https://www.ncbi.nlm.nih.gov/pubmed/16526818>.

14. Gacci M, et al. Impact of medical treatments for male lower urinary tract symptoms due to Benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. *J Sex Med* 2014; 11: 1554. <https://www.ncbi.nlm.nih.gov/pubmed/24708055>.

15. Andriole G, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. *J Urol* 2004; 172: 1399. <https://www.ncbi.nlm.nih.gov/pubmed/15371854>.

16. Naslund MJ, et al. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for The enlarged prostate. *Clin Ther* 2007; 29: 17. <https://www.ncbi.nlm.nih.gov/pubmed/17379044>.

17. McConnell JD, et al. The effect of finasteride on the risk of acute urinary retention and the Need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. *N Engl J Med* 1998; 338: 557. <https://www.ncbi.nlm.nih.gov/pubmed/9475762>.

18. Nickel JC, et al. Comparison of dutasteride and finasteride for treating benign Prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). *BJU Int* 2011; 108: 388. <https://www.ncbi.nlm.nih.gov/pubmed/21631695>.

19. Boyle P, et al. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia With finasteride: meta-analysis of randomized clinical trials. *Urology* 1996; 48: 398. <https://www.ncbi.nlm.nih.gov/pubmed/8804493>.

20. Gittelman M, et al. Dutasteride improves objective and subjective disease measures in men With benign prostatic hyperplasia and modest or severe prostate enlargement. *J Urol* 2006; 176: 1045. <https://www.ncbi.nlm.nih.gov/pubmed/16890688>.

21. Roehrborn CG, et al. Long-term sustained improvement in symptoms of benign Prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year

studies. *BJU Int* 2005; 96: 572. <https://www.ncbi.nlm.nih.gov/pubmed/16104912>.

22. Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. *BJU Int* 2008; 101(Suppl. 3): 17. <https://www.ncbi.nlm.nih.gov/pubmed/18307681>.

23. Andriole GL, et al. Effect of dutasteride on the risk of prostate cancer. *N Engl J Med* 2010; 362: 1192. <https://www.ncbi.nlm.nih.gov/pubmed/20357281>.

24. Thompson IM, et al. The influence of finasteride on the development of prostate cancer. *N Engl J Med* 2003; 349: 215. <https://www.ncbi.nlm.nih.gov/pubmed/12824459>.

25. Baldwin CM, et al. Transdermal oxybutynin. *Drugs*, 2009; 69: 327. <https://www.ncbi.nlm.nih.gov/pubmed/19275276>.

26. Michel MC, et al. Does gender or age affect the efficacy and safety of tolterodine? *J Urol* 2002; 168: 1027. <https://www.ncbi.nlm.nih.gov/pubmed/12187215>.

27. Hofner K, et al. Safety and efficacy of tolterodine extended release in men with overactive Bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. *World J Urol* 2007; 25: 627. <https://www.ncbi.nlm.nih.gov/pubmed/17906864>.

28. Kaplan SA, et al. Tolterodine extended release attenuates lower urinary tract symptoms in Men with benign prostatic hyperplasia. *J Urol* 2005; 174: 2273. <https://www.ncbi.nlm.nih.gov/pubmed/16280803>.

29. Roehrborn CG, et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. *Urology* 2008; 72: 1061. <https://www.ncbi.nlm.nih.gov/pubmed/18817961>.

30. Gacci M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. *Eur Urol* 2012; 61: 994. <https://www.ncbi.nlm.nih.gov/pubmed/22405510>.

31. Wang Y, et al. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. *Lower urinary tract symptoms* 2018; 10: 84. <https://www.ncbi.nlm.nih.gov/pubmed/293415>.

32. Porst H, et al. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract Symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. *Urology* 2013; 82: 667. <https://www.ncbi.nlm.nih.gov/pubmed/23876588>.

33. Casabe A, et al. Efficacy and safety of the coadministration of tadalafil once daily with Finasteride for 6 months in men with lower urinary tract symptoms and prostatic Enlargement secondary to benign prostatic hyperplasia. *J Urol* 2014; 191: 727. <https://www.ncbi.nlm.nih.gov/pubmed/24096118>.

34. Andersson KE. On the Site and Mechanism of Action of beta3-Adrenoceptor Agonists in